MedPath

ICMR Partners to Initiate First-in-Human Trials for Four Novel Molecules

• The Indian Council of Medical Research (ICMR) has entered into agreements to begin first-in-human clinical trials for four new drug molecules targeting various diseases. • These trials mark a significant step in indigenous pharmaceutical research and development, potentially offering new treatment options. • The partnerships aim to accelerate the clinical development process, bringing innovative therapies to patients in need more efficiently. • The molecules target conditions with unmet medical needs, reflecting ICMR's commitment to addressing critical healthcare challenges.

The Indian Council of Medical Research (ICMR) has announced partnerships to initiate first-in-human clinical trials for four novel drug molecules. This marks a significant advancement in India's pharmaceutical research and development efforts, potentially leading to new treatment options for various diseases. The agreements aim to expedite the clinical development process and bring innovative therapies to patients more efficiently.
The molecules target conditions with substantial unmet medical needs, reflecting ICMR's dedication to addressing critical healthcare challenges. While specific details about the molecules and their mechanisms of action were not disclosed, the focus on first-in-human trials suggests that these are innovative compounds with the potential to offer unique therapeutic benefits.
These partnerships underscore the importance of collaboration between research institutions and pharmaceutical companies in advancing medical science. By supporting the early-stage development of novel drug candidates, ICMR plays a crucial role in fostering innovation and improving healthcare outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cyclarity Therapeutics Launches First-in-Human Trial of UDP-003 for Atherosclerosis

Cyclarity Therapeutics has initiated a Phase 1 clinical trial in Australia to evaluate UDP-003, a drug targeting atherosclerosis.
The trial will assess the safety and potential efficacy of UDP-003 in removing arterial plaques by targeting oxidized cholesterol.

Xilio Therapeutics' Vilastobart Shows Promise in Immunotherapy-Resistant Tumors

Xilio Therapeutics announced encouraging Phase 1 data for vilastobart (XTX101) combined with atezolizumab in advanced solid tumors.
The combination demonstrated anti-tumor activity in traditionally immunotherapy-resistant tumors, including microsatellite stable colorectal cancer (MSS CRC).

PharmAbcine's PMC-403 Receives Safety Approval for 4mg Single-Dose Cohort in Phase 1 AMD Trial

PharmAbcine's PMC-403, a TIE2-activating antibody, has received safety approval for the 4mg single ascending dose cohort in its Phase 1 trial for neovascular age-related macular degeneration (nAMD).
The company is now preparing to enroll patients in the 4mg multiple ascending dose (MAD) cohort to further assess safety and efficacy.

4C Medical Initiates Enrollment in Pivotal Trial for AltaValve Mitral Valve Replacement System

4C Medical has begun enrolling patients in the ATLAS pivotal trial to assess the safety and efficacy of its AltaValve system for mitral regurgitation (MR).
The ATLAS trial includes two cohorts: patients with moderate/severe mitral annular calcification (MAC) and those without or with mild MAC.

Inimmune's INI-4001 Advances to Human Cancer Trials in Australia

Inimmune Corporation's INI-4001, a novel cancer treatment compound developed in collaboration with the University of Montana, is moving into human clinical trials in Australia.
The decision to conduct initial trials in Australia was influenced by faster trial initiation processes compared to the United States, with plans to expand to U.S. trials later.

India ICMR Partners with Industry to Advance Phase I Clinical Trials

The Indian Council of Medical Research (ICMR) has formalized partnerships with industry and academic institutions to facilitate first-in-human phase one clinical trials for four novel pharmaceutical agents.
The collaborations will support diverse research projects, including a CAR-T cell therapy study for chronic lymphocytic leukemia and trials for a small molecule targeting multiple myeloma.

ICMR Partners with Industry for First-in-Human Trials of Novel Therapies

ICMR has formalized agreements with multiple sponsors to advance four promising molecules into first-in-human clinical trials, marking a significant step for pharmaceutical innovation in India.
The collaborations include research into a small molecule for multiple myeloma, a Zika vaccine, a seasonal influenza vaccine, and CAR-T cell therapy for chronic lymphocytic leukemia.

ICMR Partners with Industry to Advance First-in-Human Phase 1 Clinical Trials in India

The Indian Council of Medical Research (ICMR) has signed agreements to advance first-in-human Phase 1 clinical trials for four molecules.
Collaborations include research for multiple myeloma, Zika vaccine development, influenza vaccine trials, and CAR-T cell therapy advancements.

Canadian Institutes of Health Research Funds Four New Clinical Trials at RI-MUHC

The Canadian government invests over $43 million in 14 new clinical trials to address health emergencies and strengthen the life sciences sector.
Researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) will lead four of these newly funded trials.

Resminostat Shows Promise in Advanced Cancers: Clinical Updates and Biomarker Identification

Resminostat combined with FOLFIRI chemotherapy demonstrates a manageable safety profile and encouraging clinical activity in patients with advanced, KRAS-mutant colorectal cancer (CRC).
A Phase I study confirmed resminostat's tolerability up to 800 mg daily with FOLFIRI, showing disease stabilization in a subset of patients treated for extended periods.

Reference News

[1]
ICMR signs agreements for first-in-human clinical trials of four new molecules
expresshealthcare.in · Sep 16, 2024

ICMR signs agreements for first-in-human clinical trials of four new molecules.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy